Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 19.14M P/E - EPS this Y 23.40% Ern Qtrly Grth -
Income -29.77M Forward P/E -0.64 EPS next Y 35.70% 50D Avg Chg 5.00%
Sales - PEG - EPS past 5Y - 200D Avg Chg -33.00%
Dividend N/A Price/Book 0.42 EPS next 5Y - 52W High Chg -65.00%
Recommedations 2.00 Quick Ratio 3.47 Shares Outstanding 2.23M 52W Low Chg 25.00%
Insider Own 4.65% ROA -38.73% Shares Float 1.93M Beta 1.85
Inst Own 15.42% ROE -76.07% Shares Shorted/Prior 26.67K/2.08K Price 0.65
Gross Margin - Profit Margin - Avg. Volume 187,970 Target Price 35.00
Oper. Margin - Earnings Date May 9 Volume 23,068 Change 0.78%
About Moleculin Biotech, Inc.

Moleculin Biotech, Inc., a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 1B/2 clinical trials for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma metastasized to the lungs. The company is also developing WP1066, an immune/transcription modulator designed to inhibit phosphorylated signal transducer and activator of transcription and other oncogenic transcription factors targeting brain tumors, and pancreatic and other cancers. In addition, it develops WP1220, an analog of WP1066 for the topical treatment of cutaneous T-cell lymphoma; and WP1122 to treat viruses, as well as cancer indications, including brain tumors, and pancreatic and other cancers. The company was incorporated in 2015 and is headquartered in Houston, Texas.

Moleculin Biotech, Inc. News
07:50 AM Moleculin Announces Formation of Scientific Advisory Board to Support Development of Annamycin
04/25/24 Moleculin Biotech (NASDAQ:MBRX) Participates in Virtual Investor "What This Means" Segment Hosted by JTC Team
04/18/24 European Medicines Agency (EMA) Grants Orphan Drug Designation for Moleculin's Treatment of Acute Myeloid Leukemia (AML)
04/10/24 Moleculin Announces Presentation of Positive Data Demonstrating High Anti-Cancer Activity of Annamycin and Non-Cardiotoxic Properties
03/28/24 Moleculin to Present at the MedInvest Biotech & Pharma Investor Conference
03/27/24 Moleculin to Participate in the Virtual Investor Lunch Break: The Moleculin Opportunity
03/27/24 Moleculin Announces U.S. Patent Issue Notification for Annamycin Targeting Unmet Need in AML
03/26/24 Moleculin Biotech, Inc. (NASDAQ:MBRX) Q4 2023 Earnings Call Transcript
03/25/24 Moleculin Announces Positive Interim Data in Annamycin MB-106 Phase 1B/2 AML Trial
03/22/24 Moleculin Biotech Inc Reports Fiscal Year 2023 Financial Results
03/22/24 Moleculin Reports Full Year 2023 Financial Results
03/20/24 Moleculin to Report Full Year 2023 Financial Results on March 22, 2024 and Host Conference Call and Webcast
03/19/24 Moleculin Announces Reverse Stock Split
03/12/24 Moleculin to Present at the 36th Annual ROTH Conference
01/24/24 Moleculin Announces 2023 Year-End Annamycin Clinical Trials Preliminary Data and 2024 Expectations for Multiple Data Readouts and Transition to Pivotal Phase 2B/3
12/20/23 Moleculin Announces Pricing of $4.5 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market
12/20/23 Here's Why We're A Bit Worried About Moleculin Biotech's (NASDAQ:MBRX) Cash Burn Situation
12/11/23 Moleculin Presents Positive Interim Data from Phase 1B/2 Clinical Trial in AML at Meeting with KOL's in Conjunction with ASH Annual Meeting
11/14/23 Moleculin Biotech, Inc. (NASDAQ:MBRX) Q3 2023 Earnings Call Transcript
11/14/23 Moleculin (MBRX) Up 7% on Upbeat Updates From Annamycin Studies
MBRX Chatroom

User Image GiraldoFetz Posted - 6 hours ago

$MBRX derrrrrr...tHiS stock OnLy G03s doowwwn...lol....πŸ˜…πŸ€£πŸ˜‚ β°οΈπŸ“ˆπŸ“ˆπŸ“ˆπŸ“ˆβ°οΈ

User Image GiraldoFetz Posted - 7 hours ago

$MBRX I'm Canadian, so my long holds are in a tfsa...otherwise just a non-reg account. πŸ“ˆ

User Image cheeseandsmile Posted - 8 hours ago

$MBRX Maxim, Roth or LPC?

User Image sprinx Posted - 8 hours ago

$MBRX https://x.com/moleculinbio/status/1785669025323749530?s=46&t=FWyCU7KfIDokGToTtqinIg

User Image GiraldoFetz Posted - 8 hours ago

$MBRX my shit swings probably.make more money than your .10 per post bash

User Image NINADRANPURA Posted - 9 hours ago

$MBRX Dr. Tallman added, β€œThe latest preliminary AML data suggest that Annamycin could result in a promising new the treatment for AML. I am excited to work alongside the Moleculin team to continue advancing its development and further explore its potential to address these areas of significant unmet need.”

User Image NINADRANPURA Posted - 9 hours ago

$MBRX Moleculin Announces Formation of Scientific Advisory Board to Support Development of Annamycin – Company appoints internationally renowned clinician, Martin S. Tallman, MD as inaugural clinician member

User Image cheeseandsmile Posted - 9 hours ago

$MBRX time to add

User Image cheeseandsmile Posted - 11 hours ago

$MBRX you are full of 🀦 http://www.stocktwits.com/FeraldoGitz

User Image brandon_lee_02 Posted - 04/30/24

$MBRX dude just get into cannabis at this point Wally

User Image shmewski Posted - 04/30/24

$MBRX

User Image GiraldoFetz Posted - 04/30/24

$MBRX can definitely say nobody is selling.

User Image NINADRANPURA Posted - 04/29/24

$MBRX completion of clinical trials

User Image jkgyuool Posted - 04/29/24

$MBRX Good thing closed above $5. Solid day

User Image bilskybill2 Posted - 04/29/24

$MBRX Losing watchers daily. Maybe it's the retard shorts leaving.

User Image GiraldoFetz Posted - 04/29/24

$MBRX such strength for such low volume. Can't wait to see what we get later this week. πŸ“ˆπŸ“ˆπŸ“ˆ

User Image GiraldoFetz Posted - 04/29/24

$VRME almost gravy time, boys!!! $BIG $MBRX $BTSG

User Image AntAlva Posted - 04/29/24

$MBRX can someone explain what the news is we’re waiting on?

User Image shmewski Posted - 04/29/24

$MBRX

User Image GiraldoFetz Posted - 04/29/24

$MBRX this is gonna go stupid when the news drops...any day πŸ“ˆπŸ“ˆπŸ“ˆ

User Image Andacagar Posted - 04/29/24

$MBRX Just imagine what real volume will do with such a low float

User Image Herbgator Posted - 04/29/24

$MBRX VOLUME

User Image sprinx Posted - 04/29/24

$MBRX https://x.com/moleculinbio/status/1784960991857361033?s=46&t=FWyCU7KfIDokGToTtqinIg

User Image GiraldoFetz Posted - 04/29/24

$MBRX that feeling you get when you're in at the bottom before news drops and a savage run....lol! πŸ“ˆπŸ“ˆπŸ“ˆπŸš€πŸŒ™β°οΈ

User Image GiraldoFetz Posted - 04/29/24

$MBRX bears blocked me because they can't handle being wrong....lol...sorry bishes. Bring the effin news and slap the piss out of those dumbfux! πŸ“ˆπŸ“ˆπŸ“ˆπŸ“ˆπŸ“ˆ

User Image GiraldoFetz Posted - 04/29/24

$MBRX derrrrrrrr....this stock only goes down...derrrrrrr...dummybear is taking another day off or what? πŸ“ˆπŸ“ˆπŸ“ˆπŸ“ˆβ°οΈ

User Image jkgyuool Posted - 04/28/24

User Image GiraldoFetz Posted - 04/28/24

$MBRX the posts below me are why I try to buy the bottom and get out if it goes south. Don't be a sour, bagholder. News soon....then a pop πŸ“ˆ...then I'll be gone and you guys can keep whining....lol

User Image Smolik Posted - 04/27/24

$MBRX disaster stock. A neverending dillution and RS machine... Garbage.

User Image jkgyuool Posted - 04/26/24

$MBRX About 1.3 million compensation for top 3 not including benefits and other stock compensation and bonuses. Probably closer to 2 million for all 3 including their bonuses. Wally needs 50 million for next 2 years to complete pivotal trial. You do the math, and this doesn’t include other people on payroll. Stock is down 70-80% + in past 5 years I believe, and they keep wanting bonuses. Keep voting them in to spend your money. I have lost faith last year in leadership. I will vote no on every one of them come next meeting

Analyst Ratings
Roth MKM Buy Apr 12, 24
Maxim Group Buy Mar 26, 24
HC Wainwright & Co. Buy Dec 14, 23
Roth MKM Buy Apr 18, 23
Oppenheimer Outperform Mar 24, 23
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Foster Jonathan P. Chief Financial Offi.. Chief Financial Officer Dec 26 Buy 0.69 28,986 20,000 80,556 12/27/23
George Robert E. Director Director Dec 26 Buy 0.69 14,493 10,000 14,660 12/27/23
KLEMP WALTER V CEO and President CEO and President Dec 26 Buy 0.69 188,404 129,999 680,880 12/27/23
KLEMP WALTER V CEO and President CEO and President Nov 25 Buy 1.2807 45,000 57,632 409,890 11/28/22
KLEMP WALTER V CEO and President CEO and President Nov 21 Buy 1.1496 22,500 25,866 364,890 11/23/22
KLEMP WALTER V CEO and President CEO and President Nov 16 Buy 1 109,955 109,955 342,390 11/18/22